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MacrophagesThere are significant numbers of nutrient sensing G protein-coupled receptors (GPCRs) that can be
found in cells of the immune system and in tissues that are involved in metabolic function, such as
the pancreas or the intestinal epithelium. The family of free fatty acid receptors (FFAR1-4, GPR84), plus
a few other metabolite sensing receptors (GPR109A, GPR91, GPR35) have been for this reason the focus
of studies linking the effects of nutrients with immunological responses. A number of the beneficial
anti-inflammatory effects credited to dietary fats such as omega-3 fatty acids are attributed to their
actions on FFAR4.This might play an important protective role in the development of obesity, insulin
resistance or asthma. The role of the short-chain fatty acids resulting from fermentation of fibre by
the intestinal microbiota in regulating acute inflammatory responses is also discussed. Finally we assess
the therapeutic potential of this family of receptors to treat pathologies where inflammation is a major
factor such as type 2 diabetes, whether by the use of novel synthetic molecules or by the modulation of
the individual’s diet.
 2016 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
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The replacement of a regular intake of healthy oils and fibres for
a diet based substantially on high fat- and high sugar-content
foods has had profound consequences for public health. These
changes in the way that the populations of high income, particu-
larly Western countries, manage their dietary habits have
undoubtedly triggered what is now considered an epidemic of obe-
sity that has consequently resulted in an increase in serious,
chronic conditions associated with dysfunctions of energy balance,
including type 2 diabetes and cardiovascular diseases [1,2]. Fur-
thermore, it is now widely accepted that low grade chronic inflam-
mation associated with obesity may be directly connected to other
inflammatory related pathologies such as asthma, colitis and,
potentially, some forms of cancer, including colon cancer [3–9].
These effects have triggered a major increase in interest with
regard to the role of metabolite sensing and how this may affect
physiology in health and disease, with concepts including the
interface between the metabolic and immune systems, i.e.
immuno-metabolism, coming to the front of scientific discussions
[9,10]. There has been particular interest in free fatty acid (FFA)
sensing and its association with the mode of signalling of a number
of recently de-orphanised G protein-coupled receptors (GPCRs)
[11]. This is a fast moving and exciting area of research focusing
the interest of pharmacologists, chemists, immunologists and
physiologists in an interdisciplinary manner. FFAs, including health
boosting omega-3 fatty acid containing oils, are therefore no longer
considered only as metabolic intermediaries but also as critical sig-
nalling molecules due to their role as agonists for different mem-
bers of the family of free fatty acid receptors (FFARs) [12–16].
Although widely expressed, their presence on key cell types regu-
lating both metabolic and immune health acts to link the regula-
tion of energy homoeostasis with the control of inflammatory
responses [17,18].
FFARs are therefore now considered very attractive targets for
the development of either novel medicines or novel strategies to
treat both metabolic and inflammatory pathologies. However, as
they are a relatively newly described group of receptors there
remain a substantial number of open questions with regard to their
function and the roles that they subserve. This reviewmaps out the
key players and connections between FFAs that are obtained
through the diet or as a result of the actions of the gut commensal
microbiota and the immune system and addresses how further
understanding of these systems might be used to limit or treat
disease.2. Overview of the family of free fatty acid receptors
2.1. Free fatty acids
The basic structure of a ‘free’ fatty acid, i.e. one unbound or non-
esterified within larger species such as triglycerides or phospho-
lipids, is a carboxylic acid linked to an aliphatic chain of variable
length that may be saturated or unsaturated. As such, fatty acids
are widely classified based on the length of their carbon chains
and grouped into short chain fatty acids (SCFAs, C2–C6), medium
chain fatty acids (MCFAs, C7–C12) and long chain fatty acids
(LCFAs, >C12). These may have a number of different origins. Most
of the ‘essential’ fatty acids such as linoleic acid (18:2, n-6) or
alpha-linolenic acid (18:3, n-3), which humans cannot synthesise
directly, and other LCFAs and MCFAs, are generally obtained
through the diet [19,20]. Some other FFAs are obtained through
the breakdown of fats (triglycerides) in adipose tissue (AT) and
the liver. By contrast the vast majority of SCFAs including acetate
(C2) and propionate (C3) are derived from the fermentation offibres and breakdown of dietary carbohydrates by the bacteria pre-
sent in the gut [21,22]. As will be discussed further, there is mount-
ing evidence to support a central role for the gut microbiota in the
regulation of energy homoeostasis and its impact in inflammatory
processes [23–25].
2.2. Free fatty acid receptors
FFARs are members of the ‘rhodopsin-like’ GPCR family and cur-
rently four receptors (FFAR1-4) are so classified. FFAR1, 2 and 3 are
closely related in terms of sequence and are co-located (on chro-
mosome 19q13.12 in humans) [26]. Between the coding regions
for FFAR3 and FFAR1 (formerly GPR41 and GPR40 respectively) in
this chromosome there is a further sequence which was considered
initially as a likely pseudogene [27]. However in recent times, anal-
ysis of this allele, which is designated as GPR42, has indicated that
it may be active in many individuals [28]. It has clearly arisen from
a tandem duplication of the FFAR3 gene as the sequence differs in
only 6 amino acids. FFAR2 (formerly GPR43) appears as the last
FFAR in the group at this genomic location. In contrast to this group
of tandemly encoded sequences, FFAR4 (formerly GPR120) is
located on chromosome 10 (10q23.33) in humans and displays lit-
tle overall homology with the other FFARs. Nevertheless, it was
identified as a receptor for LCFAs in 2005 [29]. Previous high-
throughput screening and more focussed programmes had led to
the de-orphanisation of FFAR1-3 [27,30–33] and these showed that
FFAR2 and FFAR3 respond to SCFAs of carbon chain length C2–C6,
displaying various potencies for the different ligands [27,33]. In
contrast both FFAR1 and FFAR4 are activated selectively by LCFAs.
Potentially of importance, although yet to be fully explored, human
FFAR4 is produced as two isoforms which differ structurally by a
16 amino acid insertion into the third intracellular loop of the long
isoform [34,35]. This is not present in other species investigated to
date and although these two isoforms differ in their downstream
signal transduction (see Section 2.3 and Table 1) the importance
of this for overall function remains unclear, not least because the
long isoform has only been detected in a limited number of tissues
[35,36].
Although now widely accepted, there was initially debate as to
whether the low potencies observed for most FFAs at their recep-
tors, for example propionate displays high microM to low milliM
potency at FFAR2 and FFAR3, could be reconciled with them being
the true endogenous ligands for the receptors [37]. However, levels
of SCFAs in the gut or plasma can reach high milliM levels [31,38–
41]. Moreover, LCFAs, although generally displaying low microM
potency in in vitro assays at FFAR1 and FFAR4, are highly plasma
protein bound, e.g. to serum albumin, and it remains uncertain
how this affects presentation of the ligands to the relevant recep-
tors in vivo or what are the true available ligand amounts.
The modest potency that most FFAs display at their target
receptors, and the small chemical size of the SCFAs, has resulted
in a view, although atomic level structures of these receptors are
not yet available, that the ligand pocket of FFAR2 and FFAR3 must
also be small [42]. This has resulted in challenges in terms of the
development of novel selective and potent synthetic ligands at
these receptors [43]. However, the FFAR2 antagonist GLPG0974
did enter first-in-man clinical trials, even if these were rapidly
abandoned, as a potential treatment for the lower gut inflamma-
tory condition ulcerative colitis [44] (see Section 3.1.1 for further
details). By contrast, in part because of the clear potential for reg-
ulation of glucose homoeostasis and, therefore diabetes, by target-
ing the receptors for LCFAs, the development of ligands for these
receptors is significantly more advanced [44]. For example, the
FFAR1 receptor agonist TAK-875/fasiglifam progressed into phase
III clinical trials and was able to reduce blood glucose levels,
increase insulin levels, and to cause a significant 1.2–1.4%
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caemia in type 2 diabetics. It was, however, withdrawn from these
trials due to potential liver toxicity. No selective FFAR4 ligands
have yet advanced into clinical trials, but a number have also been
shown to have positive effects on blood glucose and insulin levels
in rodent models of diabetes and obesity [44].
Although remaining officially an orphan receptor, GPR84 is a
further potential receptor for FFAs. In recent years this GPCR has
been shown to be activated by a group of MCFAs [45]. As with
FFAR4, this receptor is only distantly related to other FFAR family
members and was originally isolated using an in silico EST data
mining strategy [46] designed to identify GPCR sequences that
were divergent in sequence from those identified previously.
Although the chain length selectivity of fatty acids at GPR84 is very
narrow [45], meaning that it is activated only by a small group of
fatty acids, various synthetic molecules have been shown to pro-
mote activation [44] and, therefore, provide a wider pharmacology
to explore the functions of this receptor.2.3. Signal transduction and expression of FFARs
The most common feature of GPCRs is their ability to signal
through the activation of heterotrimeric G proteins (Table 1). The
four FFARs are no exception and show diverse coupling preferences
to G proteins as well as also promoting a variety of G protein-
independent pathways. Both of the SCFA receptors, FFAR2 and
FFAR3, have an established preference for coupling to pertussis
toxin-sensitive Gai/o G proteins that results in inhibition of adeny-
lyl cyclase and a reduction in cAMP production. However, FFAR2 is
more pleiotropic than FFAR3 and is also able to couple to Gaq/11 G-
proteins with subsequent elevation of intracellular calcium [47]. As
well as sharing coupling to Gai/o G proteins FFAR2 and FFAR3 have
overlapping patterns of expression as both can be found in adipo-
cytes, pancreatic islets and in several incretin-releasing enteroen-
docrine cells such as K cells (gastric inhibitory polypeptide (GIP)
release), I cells (cholecystokinin (CCK) release), and L cells
(glucagon-like peptide-1 and peptide YY (GLP-1 and PYY) release)
[27,43,48,49]. In recent years immunologists and computational
biologists have joined forces to compile gene expression profiles
of immune cell populations from mice in efforts to define potential
inflammatory profiles and targets. Data from this consortium
(www.immgen.org) indicate two key populations of immune cells
where FFAR2 is heavily expressed: neutrophils and mesenteric and
small intestine dendritic cells (DC). More specifically FFAR2
expression is found in CD11b+ neutrophils from blood and synovial
fluid and resident macrophages from adipose and lung tissues also
show a relatively high level of FFAR2 expression. FFAR3 expression
can be found in sympathetic ganglia [48] and the enteroendocrine
cells mentioned above [27,43,48,49], although datasets from the
Immunological Genome Project also indicate expression broadly
but at low levels in white cells, in DCs and some subclasses of neu-
trophils (Table 1).
FFAR1 is found in pancreatic islets, with particularly enriched
expression in the b-cells which produce and release insulin and,
therefore, its function has been linked to the modulation of
glucose-stimulated insulin release [31,50,51]. This receptor is
expressed together with FFAR4 in enteroendocrine cells of the gas-
trointestinal tract where it mediates FFA-stimulated incretin secre-
tion [52–54]. FFAR4 is also found in the pancreas, where
expression is suggested to be restricted to the d-cells [55], in adipo-
cytes, lung [35,56] and in immune cells, particularly CD11c+ bone
marrow-derived macrophages and intra-peritoneal-derived
macrophages [57]. The distribution of FFAR4 expression is sup-
ported by reports available via the Immgen database, where FFAR4
expression is also noted to be present in a number of types of DCs(mesenteric, lung CD11b+, small intestine) and, in particular, in
lung-resident macrophages (Table 1).
Macrophages are generally found as heterogeneous mixed pop-
ulations and based on gene expression patterns have been cate-
gorised into two activation/polarisation states, namely classic
(M1) or alternative (M2) [58–60]. The release by Th1 helper cells
of inflammatory cytokines such as interferon-gamma (INFc) during
the initial phases of acute inflammation promotes polarisation into
activated M1 macrophages, whereas anti-inflammatory cytokines
(IL-4, IL-13), released by Th2 helper cells, drive polarisation
towards the M2 phenotype [57,61,62]. This leads towards the res-
olution of the inflammatory process via the activation of peroxi-
some proliferator-activated receptor gamma (PPARc). Expression
of FFAR4 in different types of macrophages (monocytes, Kupffer
cells in the liver, osteoclasts in the bone, resident macrophages
in the lung) and its potential to regulate inflammation (see Sec-
tion 3.2.2) make this receptor a very exciting target for the devel-
opment of novel compounds to treat metabolic syndrome and its
many ramifications [14,63–65] (Table 1).
As previously alluded to, G protein-independent signalling
mechanisms are often important for GPCR function and although
FFAR1 and FFAR4 signal predominantly via Gaq/11 G proteins
[30,31,50,54] they are also able to signal via the recruitment of
b-arrestin-2 [66–69]. b-Arrestins are scaffold proteins that histori-
cally have been studied largely in relation to their capacity to
induce receptor desensitisation and internalisation processes that
frequently follow receptor activation by agonists [70–75]. How-
ever, it is now abundantly clear that b-arrestins also function as
part of alternative signalling cascades [70,73,76–78], leading to
the activation of a myriad of effector enzymes, including protein
kinases of the mitogen activated family such as the extracellular-
signal regulated kinases 1 and 2, the c-Jun kinases and the
stress-activated p38 kinases [79–81]. Of the four FFARs, FFAR3
appears to be the one with the least propensity for b-arrestin
recruitment in response to ligand activation as there are currently
no reports to this effect. Nonetheless, signalling through this arm
seems to be important for the function of the other three receptors,
especially for FFAR4 where the divergence between G protein- and
b-arrestin-dependent pathways seems to be cell type dependent
and critical for the regulation of metabolic or inflammatory pro-
cesses [57]. It is worth noting that the long isoform of FFAR4 that
can be found in human colon [36] is reported to almost exclusively
engage with the b-arrestin pathway, leading to receptor internali-
sation when over-expressed in a recombinant system whilst it
seems to be impaired in G protein coupling as evaluated in intra-
cellular Ca2+ release and dynamic mass redistribution (DMR)
assays [29,30,82]. This may reflect that the 16 amino acid insertion
that produces the long isoform is located within the third intracel-
lular loop, an important element in receptor function. Although the
insertion introduces additional potential phosphorylation sites this
does not to have a substantial effect on the overall capacity for b-
arrestin recruitment [34,82]. Agonist-induced phosphorylation and
subsequent recruitment of b-arrestin largely reflects post-
translational modification of amino acids within the C-terminal tail
of FFAR4 [83,84] which is identical between the isoforms (Table 1).3. The role of free fatty acid receptors in metabolism and
immune responses
3.1. Short-chain free fatty acid receptors in immune cell signalling and
regulation
Although both SCFA receptors, FFAR2 and FFAR3, are co-
expressed in certain cells and tissues, such as pancreatic a and b
cells and some enteroendocrine cells, as noted earlier, FFAR2 in
Table 1
Summary of FFA receptors, signalling properties and functions.
Receptor Agonists Signalling Immune cells Function Immune system Other functions tissues/cells
FFAR1 LCFA (>C12)
Natural: palmitic acid, oleic acid, pinolenic acid, aLA,
DHA
Synthetic: GW9508, TAK-875/Fasiglifam, AMG-837,
AM-5262, TUG-424, TUG-770
Gaq/11#
Gai/o
b-arrestin-2
– – Improved GSIS
Increased incretin release
Enteroendocrine L, K and I-cells
Pancreatic b-cells
Taste buds
FFAR2 SCFA (C2–C6)
Natural: formate, acetate#, propionate, butyrate
Synthetic: 4-CMTB
Gai/o#
Gaq/11
Neutrophils, intestinal Treg cells,
eosinophils, macrophages,
dendritic cells
Regulation of inflammatory
processes in the gut
Control of epithelial integrity
Neutrophil chemotaxis
Epithelial colonic cells
Adipocytes
Enteroendocrine L, K and I-cells
Pancreatic a and b-cells
FFAR3 SCFA (C3–C7)
Natural: acetate, propionate#, butyrate
Synthetic: AR420626
Gai/o – Regulation of inflammatory
processes in airways
Enteroendocrine cells
Sympathetic ganglia
FFAR4 (short) LCFA (>C12)
Natural: aLA, DHA, EPA
Synthetic: GW9508, TUG-891, Compound A, NCG 21
Gaq/11
b-arrestin-2
Dendritic mesenteric, lung
CD11b+ cells, small intestine
cells, bone marrow-derived and
intra-peritoneal derived
macrophages, Kupffer cells,
eosinophils
Anti-inflammatory effects in the
gut and adipose tissue
Incretin mediated regulation of insulin
secretion (increased GLP-1 release)
Adipocytes
Enteroendocrine L, K and I-cells
Pancreatic d cells
Clara/Club lung cells
Taste buds
FFAR4 (long) LCFA (>C12)
Natural: aLA,DHA, EPA
Synthetic: GW9508, TUG-891
b-arrestin-2 – – Increased incretin release (GLP-1)
Enteroendocrine L-cells
GPR84 MCFA (C7-C12)
Natural: capric/decanoic acid, undecanoic acid
Synthetic: DIM, 6-OAU
Gai/o Macrophages, neutrophils, T-
cells, glial cells
– Adipocytes
Sciatic nerve
Microglia
# Preferred; aLA, a-linolenic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; DIM, diindolylmethane; 6-OAU: 6-n-octylaminouracil; GSIS: glucose stimulated insulin secretion. See text for details on references.
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including neutrophils, eosinophils, monocytes and, quite impor-
tantly, epithelial colonic cells, where it may play a role in maintain-
ing epithelial integrity and in intestinal Treg cells [85–90].
3.1.1. Roles of FFAR2 receptor in inflammatory processes related to the
gut and other tissues
There is a growing belief that a healthy gut microfloral popula-
tion can positively influence immune responses such that the indi-
vidual might be protected from the development of inflammatory
pathologies such as ulcerative colitis, arthritis or even asthma, with
a growing number of studies linking general wellbeing and healthy
gut function with highly diverse intestinal microbiota and intake of
fibre in the diet [1,91–93]. Bacteria belonging to the Bacteroidetes
and Firmicutes phyla have been found to produce high levels of
the SCFAs C2–C4 which are the main agonists for FFAR2. Levels
of these SCFAs in the intestinal tract can vary depending on the
bacterial composition within individuals and dietary habits but
they reach the systemic blood circulation in sufficiently high levels
to activate these receptors. However, the molecular link between
microbiota SCFA production, FFAR2 function and immune regula-
tion had not been clear until recently. In studies carried out using
FFAR2 knock-out and germ-free mice, Maslowski and colleagues
[94] showed that FFAR2 was necessary for the resolution of a num-
ber of inflammatory responses in models of colitis, asthma and
arthritis. Chemically-induced colitis in germ-free mice that lack
the ability to produce any SCFAs due to the absence of the gut
microbiota resulted in an exacerbated inflammatory phenotype
that could be all but reverted to that of the wild type by supple-
menting the drinking water with 150 mM acetate. This was accom-
panied by a reduction in levels of inflammatory mediators such as
tumour necrosis factor alpha (TNFa), myeloperoxidase (MPO) and
the chemokine CCL3. On the other hand, inflammation was not
resolved in the FFAR2 knock-out mice, providing further evidence
that the effect observed in the germ-free mice treated with acetate
was FFAR2 mediated [94]. This report and others also showed that
neutrophil chemotaxis to SCFA agonists in a transwell-based Boy-
den chamber was lacking in cells produced from FFAR2 deficient
mice [87,94]. At the molecular level this chemotactic effect is likely
to reflect the activation of the p38 MAP kinase cascade, a pathway
known to mediate chemotaxis in cells of the immune system
[87,95]. Despite the elegant studies of Maslowski et al. [94] con-
flicting results have been reported. For example, [87] noted a detri-
mental effect of FFAR2 on polymorphonuclear leucocyte (PMN)
infiltration that could lead to more severe tissue damage and,
therefore, less receptor-mediated beneficial effects. This clearly
poses challenges for the potential development of FFAR2 selective
medicines for the treatment of intestinal inflammatory pathologies
such as irritable bowel disease (IBD) because it is unclear from the
above whether an FFAR2 antagonist might be beneficial or contra-
indicated. One potential scenario is that if inflammatory processes
induced by infiltration of PMNs and other immune cells in
response to cytokines are driven by the activation of FFAR2 then
inhibition of this receptor would prevent this from happening. As
noted earlier this hypothesis was assessed recently by the develop-
ment and clinical trial of the FFAR2 antagonist GLPG0974. How-
ever, no improvements of clinical symptoms were reported
during a 4 week treatment period, resulting in the termination of
the study. Nevertheless, in pre-clinical studies this molecule was
able to efficiently inhibit acetate-induced chemotaxis of human
neutrophils in vitro, to block acetate-mediated elevation of intra-
cellular calcium in HEK293 cells transfected to express FFAR2 with
potency in the nanoM range and to regulate expression of CD11b,
an activation specific marker (CD11b[AE]) used as an indicator of
neutrophil adhesion to the endothelium and extravasion towards
inflamed tissues [96]. It may be, therefore, that currentunderstanding of the biology of FFAR2 is incomplete or over-
simplistic. Moreover, there may well be significant species
variability in disease pathology and progression and because
GLPG0974, although a high affinity antagonist of human FFAR2,
does not show significant affinity at mouse or rat FFAR2 [97], no
pre-clinical effectiveness in these species could be assessed prior
to the first-in-man trials.
FFAR2 function has also been linked to non-gut related inflam-
matory processes such as gouty arthritis. Vieira and co-workers
have suggested that FFAR2 is responsible for the amplification of
acute inflammation in a rodent model, through the regulation of
NLRP3 inflammasome assembly [98]. FFAR2 expression was upreg-
ulated in the knee tissue of mice injected with monosodium urate
monohydrate (MSU). Furthermore FFAR2 knockout mice showed
significantly less IL-1b production and subsequent neutrophil
migration to the MSU injected joints. These authors proposed the
idea that the gut microbiota and its products might shape the abil-
ity of the host to respond to inflammasome-mediated processes
[98]. However, most of the data were only indirectly related to sig-
nalling from FFAR2 and hence caution is required in interpreting
these data. Despite this, the fact that FFAR2 expression can be read-
ily detected in the neutrophils of synovial fluid may indicate a role
for the receptor in the joints. Nonetheless, this highlights ideas that
may lead to new investigations in NLPR3 inflammasome biology
and also of FFAR2-mediated disorders related to diet-induced
pathologies [99].
From a molecular perspective, implications of interactions
between FFAR2 and b-arrestin-2 are poorly understood
[100,101]. However, FFAR2 can clearly interact with b-arrestin-2
(there is less information on interactions with b-arrestin-1) and
in so doing can modulate the activity of nuclear factor jB (NF-
jB) [101]. Although a full description of how the receptor might
regulate this pathway is uncertain it may provide a novel avenue
to study further potential anti-inflammatory effects of FFAR2.3.1.2. FFAR3 is a key player in airway inflammation
FFAR3 may also be a key player in inflammatory processes. In
airway inflammation the intestinal microbiota composition, fibre
content of the diet and subsequent SCFA production can have a
profound impact on the immunological makeup of the lungs and
has been suggested to regulate inflammation during induced aller-
gic asthma [102]. A relation between dietary fibre, FFAR3 function
and susceptibility to allergic airway inflammation was found in
studies in which mice were provided with either a regular content
of fibre in their diets (4%) or fed low-fibre diets (<0.3%). Animals
maintained on low-fibre diets displayed an increase in white cell
infiltration in the lungs as well as the production of a variety of
cytokines (IL-4, IL-13, IL-5, IL-17A) following airway inflammation
induced by the administration of house dust mite (HDM). These
effects were reversed by changing diet to contain the highly fer-
mentable fibre pectin [102]. Further experiments to elucidate the
mechanisms by which SCFAs derived from the dietary fibre control
airway inflammation involved treatment of wild type and FFAR2-
or FFAR3-deficient mice with C3, (which can activate either
receptor), prior to exposure to HDM. A reduction in inflammation
markers (e.g. eosinophil infiltration, goblet cell hyperplasia) was
observed in the case of the wild type and FFAR2-deficient mice
treated with C3 but not the FFAR3 knock-out animals, where there
were no differences between the SCFA-treated and un-treated
groups. Notably, C3 changed the balance between resident DCs
found in the lung and those that migrate to it after the onset of
inflammation. It is possible that precursors of macrophages and
DCs in the bone marrow migrate to mitigate the Th2 pro-
inflammatory allergic response driven by the presence of SCFAs
acting on FFAR3.
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has also been examined as this group is reported to have large pop-
ulations of anaerobic bacteria present in the lungs due to the
hypoxic environment developed under this condition [103,104].
These studies confirmed that the lungs are far from sterile and con-
tain sufficient anaerobic bacteria, able to produce SCFAs at milliM
concentrations, as detected in the broncho-alveolar fluid from CF
patients. It remains unclear, however, how these bacteria come
in contact with potential substrates to produce the SCFAs. These
studies also demonstrated that CF patients display elevated levels
of FFAR3 expression [103] and that bronchial epithelial cells from
this group were able to release more of the pro-inflammatory cyto-
kine IL-8 upon stimulation with SCFA compared to non-CF
patients. siRNA knock-down of FFAR3 reduced production of the
cytokine [103].
Although this is a rapidly developing area it is already clear that
FFAR2 and FFAR3 provide the molecular targets within an emerg-
ing gut-lung axis that regulates the balance between pro- and
anti-inflammatory processes between the two mucosal tissues
and this may be influenced greatly by the diet and composition
of the intestinal microflora.
3.2. Medium and long-chain free fatty acid receptors in immune cell
signalling and regulation
3.2.1. Roles of GPR84, a newly described MCFA receptor, in immunity
The MCFA receptor GPR84 displays an interesting tissue distri-
bution, found mostly on cells of the immune system such as neu-
trophils, T-cells, macrophages, including glial cells [12,105–107].
GPR84 expression is also found in adipocytes [105,108] and
although still poorly defined, its function has been linked to pro-
inflammatory phenotypes [108–111]. Expression of GPR84 has also
been found by PCR studies in the spinal cord and sciatic nerve of
mice, which has triggered some investigations into a putative role
in pro-nociceptive pathways [112]. According to some the role
GPR84 is directly connected to immune function and metabolic
dysregulation [45,108,110]. GPR84 expression is upregulated in
macrophages by the presence of lipopolysaccharide (LPS)
[45,106] where it also seems to mediate the release of the pro-
inflammatory cytokine IL-12. IL-12 and its regulation of the bal-
ance (Th1/Th2) of T helper responses play an important role in
inflammatory diseases such as rheumatoid arthritis and IBD, and
a potential role of GPR84 in this context has been supported by evi-
dence that shows an increase in Th2 (IL-4) cytokine production in T
cells derived from GPR84 knock-out mice [111]. Furthermore, LPS-
stimulated macrophages derived from GPR84 knock-out mice
show markedly reduced expression of several pro-inflammatory
mediators [112].
Whilst GPR84 is, to date, the least studied of the FFA-regulated
GPCRs, members of the family that respond to LCFAs have been
more widely studied and their links to immune function are
becoming better established. FFAR1 and FFAR4 can be activated
by a broad range of both saturated and unsaturated LCFAs [113]
but there has been a special focus on FFAR4 and the actions that
both omega-3 and omega-6 PUFAs may exert via this receptor.
Omega-3 fatty acids, such as docosahexaenoic acid (DHA) present
in high levels in fish oils and a-linolenic acid present in some veg-
etable and nut oils, have increasingly been promoted as healthy
supplements and dietary sources rich in these fatty acids have
become fashionable ‘‘super-foods” in recent years [113–116]. This
has been supported by a number of studies that suggest a link
between inflammation and saturated fats, as these promote
inflammation via Toll-like receptors [117], and the protective,
anti-inflammatory effects of omega-3 fatty acids such as DHA on
adipoctyes and macrophages [57,62,118–120]. Although FFAR4
responds in very similar ways to saturated, omega-6 andomega-3 fatty acids when expressed in recombinant systems, in
cells expressing endogenous levels of the receptor, such as the
murine enteroendocrine cell line STC-1, it is reported that only
the omega-3 LCFAs are able to produce convincing evidence of
FFAR4-mediated beneficial effects, such as release of the incretin
GLP-1 [29]. Moreover, evidence supporting an anti-inflammatory
role for the receptor has been shown in the model macrophage-
like cell line RAW264.7 where relatively high levels of FFAR4 are
expressed. Here, stimulation with the synthetic agonist GW9508,
which activates FFAR4, is able to inhibit LPS-mediated release of
the inflammatory cytokines TNF-a and IL-6 [57].
3.2.2. FFAR4 receptor: the paradigm of an anti-inflammatory mediator
with important metabolic consequences
The role of FFAR4 in metabolic function has been analysed in
detail using FFAR4 deficient mouse models [121,122]. When FFAR4
knock-out mice were subjected to a high fat diet, they developed
obesity, glucose intolerance and fatty liver to a higher degree than
wild type animals. These mice displayed exacerbated insulin resis-
tance and, furthermore, they had a higher proportion of pro-
inflammatory infiltrated macrophages in the AT [122]. In humans
it has been shown that FFAR4 expression is upregulated in the
AT of obese individuals. Furthermore, in a French population, those
carrying a single amino acid variation (reported as Arg270His,
which corresponds to Arg254His in the more common short iso-
form) in the FFAR4 gene are reportedly at a higher risk of develop-
ing obesity [122]. Although these findings suggest a potentially
causative link between obesity, the development of insulin resis-
tance and a fundamental role for the nutrient-sensing FFAR4 as a
protective element [122], this polymorphism is uncommon in
other populations, being virtually absent in a Japanese study and
a more recent study noted a lack of linkage to the risk of type 2 dia-
betes or variation of fasting insulin levels [123]. Despite this, FFAR4
expression is found in isolated AT stromal vascular fractions, that
contains macrophages that can account for as much as 40% of the
total number of cells in obese AT [124], and it is also found in
the resident hepatic macrophages, known as Kupffer cells, in high
fat diet-induced obese mice [57,62,125]. In summary, the presence
of FFAR4 in macrophages and its role in regulating their ability to
migrate to other tissues, coupled with the balance of macrophage
phenotypes have resulted in a number of proposals that link these
phenomena to the function of FFAR4 and the pathological ramifica-
tions of obesity.
Other evidence supports that underlying chronic inflammation
experienced by the adipose and hepatic tissues of obese individu-
als may lie at the core of the development of type 2 diabetes [126–
128]. Inflammatory responses should be considered as multistep
processes. In general, the onset of an inflammatory response com-
prises an increase of tissue vascularisation, followed by enhanced
permeability of the vascular wall that allows the endothelial cross-
ing of large molecules (chemo-attractants, cytokines, chemokines).
Subsequently, the migration of white cells to the site of inflamma-
tion in response to released mediators resumes and there is the
possibility of either resolution of the inflammation through the
production of resolvins or maintenance of the inflammatory sig-
nals (prostaglandins, leucotrienes, cytokines, chemokines) depend-
ing on the tissue and cells involved in the process [8,129,130]. The
infiltration of cells of the immune system, including macrophages,
towards the hypertrophic AT is prompted by the release of cytoki-
nes and chemokines (e.g. MCP-1, LTB4) [131]. The infiltrated acti-
vated macrophages release more cytokines (e.g. TNF-a)
[128,132,133] that may have paracrine effects on neighbouring
cells and endocrine actions on insulin-target cells (e.g. adipocytes,
hepatocytes and muscle cells). The maintenance of this cycle of
pro-inflammatory signals in the longer term promotes the devel-
opment of insulin resistance [134]. From a molecular perspective,
Fig. 1. FFAR4-mediated anti-inflammatory effects in macrophages. Macrophages expressing FFAR4 respond to omega-3 fatty acids that activate the receptor eliciting
phosphorylation of the carboxyl-terminal tail (represented by red dots), subsequent b-arrestin-2 recruitment and receptor internalisation. At this point the receptor-b-
arrestin-2 complex interacts with the TAB-1 protein, that is taken into the endocytic vesicle, making it unavailable to activate the TAK-1 protein responsible for the
transduction downstream of signalling coming from activated Toll-like and TNFa receptors. This further blocks the NF-jB/JNK cascades, therefore inhibiting inflammatory
responses in these cells. (LCFA, long chain fatty acid; x-3-FAs, omega-3 fatty acids, TLR2/4, Toll-like receptors 2 and 4, TNFR, TNFa receptor).
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are regulated via the actions of LPS and TNF-a on Toll-like recep-
tors (TLR2 and TLR4) and tumour necrosis factor receptor (TNFR)
respectively and subsequent activation of the I kappa B kinase-b
(IKK b)/NF-jB and JNK cascades [135,136]. The activation of IKK
b-dependent pathways in macrophages has been shown to be suf-
ficient for the development of insulin resistance in obesity due to a
central role of this kinase as controller of many inflammatory
responses. Studies using mice that lacked functional IKK b protein
in either hepatic cells or in myeloid cells where NF-jB activation
induces inflammatory mediators that cause insulin resistance,
showed that IKK b plays a central role in the development of insu-
lin resistance at a systemic level, as mice that had lost IKK b func-
tion in bone marrow-derived myeloid cells (Ikbkb[Dmye]) retain
insulin sensitivity and are less prone to develop obesity [137].
Agonist stimulation of FFAR4 mediates signalling through Gq/11
activation or through its interaction with b-arrestin proteins but it
is the G protein-independent signalling pathway that is believed to
be responsible for the anti-inflammatory properties of the receptor
in macrophages (Fig. 1). Relatively recent studies show that inflam-
matory processes in macrophages are regulated via the activation
of FFAR4 [57,62]. This is a b-arrestin-2 dependent process and
places FFAR4 upstream from a common node of both IKK b /NF-
jB and JNK pathways [57,62]. Mechanistically it has been pro-
posed that FFAR4 activation and concomitant recruitment of b-
arrestin-2 promotes further interactions between b-arrestin-2
and TAB-1, the transforming growth factor kinase protein (TAK-
1) binding protein, which acts as activator of TAK-1. This receptor
mediated b-arrestin-2-TAB-1 interaction is suggested to prevent
the formation of a TAB-1/TAK-1 complex and halts the subsequent
relay of signalling that results in the inflammatory response (Fig. 1)[57]. If either FFAR4 or b-arrestin-2 were reduced in amount, pro-
duced via introduction of siRNA against these proteins, there was
an increase in LPS-mediated TNF-a release after stimulation with
the omega-3 fatty acid and FFAR4 agonist DHA in RAW264.7 cells
[57]. b-Arrestin-2 pull-down experiments demonstrated the phys-
ical interaction between b-arrestin-2 and the FFA4 receptor and
also with TAB-1 in both cells heterologously expressing these pro-
teins, and in RAW264.7 cells, after stimulation with DHA, or DHA
plus LPS respectively [57]. Similar results have been reported using
a synthetic agonist of FFAR4 to replace the fatty acid [57]. Com-
pound A (cpdA), is bioavailable and has reasonable potency at
FFAR4 but lacks activity at FFAR1 [62]. This molecule produced
anti-inflammatory effects in macrophages in both in vitro and
in vivo models [62]. Treatment of primary macrophages with cpdA
in conjunction with LPS inhibited phosphorylation of many of the
previously discussed phospho-regulated kinases that are typically
activated in inflammatory processes (e.g. p-IKK, p-JNK, pTAK-1)
[62]. Furthermore, treatment with this compound blocked chemo-
taxis of macrophages towards adipocytes in co-culture experi-
ments employing adipocyte-derived conditioned medium and
this was lacking if the macrophages were derived from an FFAR4
knock-out mouse [62]. This is clearly consistent with FFAR4 activa-
tion regulating macrophage infiltration into AT [62]. Although, as
discussed earlier, FFAR4 does not respond only to omega-3 fatty
acids [66,113] studies with mice sustained on omega-3 fatty
acid-enriched diets also showed decreased macrophage chemo-
taxis and infiltration into AT in general and a decrease in inflam-
matory markers typically found in M1 polarised macrophages
[57,138]. Equivalent experiments performed in vivo, where isolated
wild type circulating monocytes were labelled with a fluorescent
dye and were re-injected into either wild type or FFAR4
10 E. Alvarez-Curto, G. Milligan / Biochemical Pharmacology 114 (2016) 3–13knock-out mice which were subsequently maintained on a high-fat
diet, and omega-3-enriched diet or treated with cpdA showed a
marked decrease in the AT infiltrated macrophages in wild type
animals that were treated with either omega-3-enriched diet or
with cpdA, whilst there were no differences in the FFAR4-
deficient mice [62]. This once more highlights the role of FFAR4
in mediating macrophage infiltration of AT.
This is of significance as the majority of the infiltrated macro-
phages found in obese AT tend to be CD11c+, M1-like, macrophages
[124], due to the nature of the adipokines and cytokines released in
this tissue, whereas alternatively activated M2-macrophages tend
to reside in healthy AT [58,139,140]. Moreover, a new subtype of
macrophage, that differs from the M1 phenotype, has been recently
described that develops under metabolic activation conditions
(high FFA concentrations, high glucose and insulin) and is associ-
ated with a pro-inflammatory phenotype [59]. This
metabolically-activated macrophage has been shown to express
distinct surface marker proteins and is able to secrete pro-
inflammatory cytokines including IL-1b, in a PPARc-dependent
manner [59]. However, to date, expression patterns of the FFAR
receptors, and more specifically of FFAR4, has not been shown
for this subtype.
Based on the foregoing, selective small molecule agonists of
FFAR4 might be useful tool compounds to assess effects of limiting
macrophage migration into the AT and to regulate the phenotypi-
cal switch between M1/M2 macrophages that has been linked to
the development of further inflammation and insulin resistance
[139], as well as having an insulin sensitising effect.
Further supporting a central role of FFAR4, and of FFAR1, in
anti-inflammatory processes there have been a number of studies
describing the mechanisms by which omega-3 fatty acids suppress
inflammation by inhibiting the activation of the NLRP3 inflamma-
some acting predominantly via an arrestin-FFAR4 dependent path-
way [140]. This provides a novel anti-inflammatory mechanism of
action of FFAs, in particular omega-3 fatty acids. Activation of the
NLPR3 inflammasome in response to either pathogens or danger
associated molecular patterns triggers a caspase-1-dependent cas-
cade that leads to the release of pro-inflammatory cytokines such
as IL-1b, IL-33 and IL-18. This increase in levels of pro-
inflammatory cytokines has been linked to the development of
insulin resistance in chronic hyperglycaemic conditions, and ele-
vated levels of IL-1b have been found at the onset of type 2 dia-
betes in obese individuals [141]. Moreover, the NLRP3
inflammasome is not solely involved in host defence but also in
auto-inflammatory disorders, therefore further insights into how
these processes are regulated will be key to developing novel ther-
apeutics. The studies described in [140] show that both the natural
ligand DHA and the small synthetic agonist molecule GW9508, act-
ing at either FFAR1 or FFAR4, are able to suppress caspase-1 activa-
tion and IL-1b and IL-18 secretion in LPS-primed bone marrow-
derived macrophages, where expression of FFAR4 in particular is
high. Equivalent experiments performed in human monocytic
THP-1 cells confirmed these findings and additional studies in this
cell line when either FFAR1 or FFAR4 expression was knocked-
down using shRNA technology demonstrated an additive effect of
both receptors in the inhibition of inflammasome activation and
suppression of the release of IL-1b. This has led to suggestions that
the high level of inflammation found in AT reported as part of the
phenotype of FFAR4 knock-out mice [122] reflects failure to inhibit
the NLRP3 inflammasome actions in this context [140]. It was also
noted in this work that silencing of b-arrestin-2 expression, a crit-
ical component of the downstream FFAR4 anti-inflammatory path-
way, in THP-1 cells cancelled the inhibitory effect of DHA on NLRP3
and NLRP1b (another subtype of inflammasome complex) activa-
tion. Furthermore b-arrestin-2 forms a complex with either NLRP3
or NLRP1b after DHA treatment but not with some of the othermembers of the inflammasome proteins (NLRC4 or AIM2). Finally,
it was shown in wild type mice fed a high-fat diet that there were
improvements in insulin resistance when the diet was supple-
mented with DHA but this was without effect in Nlrp3/ mice.
On this basis, the authors proposed that omega-3 fatty acids are
able to block metabolic stress and inflammation derived from the
activation of the NLRP3 inflammasome and potentially have bene-
ficial effects on high-fat-induced insulin resistance [140].
Expression of FFAR4 is not restricted exclusively to
macrophages/monocytes as recently expression of this receptor
has been described in human eosinophils isolated from peripheral
venous blood and visceral AT [142,143]. This class of granulocyte is
normally found at low levels in the circulation but it can accumu-
late in certain tissues, such as the gastro-intestinal tract and the
lungs. Eosinophils can play a positive role in clearing infection,
but in pathologies such as asthma, they have typically been associ-
ated with Th2-mediated airway inflammation [144,145]. Eosino-
phils are also present in visceral AT under normal conditions,
where they help maintain glucose homoeostasis through the stim-
ulation of alternative polarisation of macrophages in a Th2-
dependent manner through the release of IL-4 [143]. Konno and
co-workers reported a strong down-regulation of FFAR4 expression
on the surface of isolated human blood eosinophils after treatment
with the FFAR4 active agonist GW9508. This is anticipated as rapid
agonist-induced internalisation of FFAR4 has been reported in
many settings [66,82,146]. The role of FFAR4 in eosinophil chemo-
taxis remains uncertain, however, but the receptor may play a role
in suppressing eosinophil apoptosis [142], which may be relevant
to control of the lifespan of eosinophils in adipose and gastroin-
testinal tissues.
4. Conclusions and final remarks
It was already clear from early studies on the expression pro-
files in various immune cell populations of each of the SCFA recep-
tor FFAR2, the MCFA receptor GPR84, and the LCFA receptor FFAR4,
that these receptors would likely play important roles in immune
cell function. However, in recent times a broad swathe of studies
have confirmed and built on these predictions. In concert with
improving understanding of the roles that these, and the other
FFARs, play in other cell types and tissues in providing a means
to sense metabolite availability then an emerging view is that they
act to regulate the metabolic-inflammatory axis. Given that aspects
of inflammation underlie many chronic and co-morbid diseases,
including type II diabetes, and obesity, there is considerable antic-
ipation that agonist and/or antagonists of these receptors may play
important roles in further understanding this interface and poten-
tial in the therapeutic treatment of such diseases.
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